Cogent Biosciences, Inc. (COGT)
| Market Cap | 5.94B +1,055.5% |
| Revenue (ttm) | n/a |
| Net Income | -354.30M |
| EPS | -2.51 |
| Shares Out | 170.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 896,097 |
| Open | 34.94 |
| Previous Close | 34.79 |
| Day's Range | 34.47 - 35.40 |
| 52-Week Range | 4.55 - 43.73 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 36.43 (+4.87%) |
| Earnings Date | May 5, 2026 |
About COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price target is $36.43, which is an increase of 4.87% from the latest price.
News
Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Cogent Biosciences (COGT) to $55 from $52 and keeps a Buy rating on the shares following the Q1 report.
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation...
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences announces preclinical data from KRAS, ErbB2 programs
Cogent Biosciences (COGT) announced that preclinical data from the Company’s KRAS and ErbB2 pipeline programs will be presented during poster sessions at the American Association for Cancer Research, ...
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors
Cogent Biosciences submits bezuclastinib new drug application to the FDA
Cogent Biosciences (COGT) announced the completion of the submission of its new drug application to the FDA for bezuclastinib in patients with Gastrointestinal Stromal Tumors who have received prior t...
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences assumed with a Buy at Jefferies
Jefferies analyst Faisal Khurshid assumed coverage of Cogent Biosciences (COGT) with a Buy rating and $55 price target The firm views Cogent as “one of the cleanest late-stage biotech setups.”
Cogent Biosciences: FDA accepts NDA for bzuclastinib in NonAdvSM
Cogent Biosciences (COGT) announced that the U.S. FDA has accepted its New Drug Application for bezuclastinib in patients with NonAdvanced Systemic Mastocytosis and assigned a Prescription Drug User F...
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026
Bezuclastinib is positioned for commercial launch in three indications following positive pivotal trials, with strong differentiation from competitors and significant market opportunities in rare diseases. Commercial infrastructure is advancing, and the pipeline is being refined to focus on the most promising assets.
Cogent announces additional results from SUMMIT trial of bezuclastinib
Cogent Biosciences (COGT) announced additional clinical results from the SUMMIT trial with bezuclastinib in patients with NonAdvanced Systemic Mastocytosis at the American Academy of Allergy Asthma & ...
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences price target raised to $35 from $34 at Baird
Baird raised the firm’s price target on Cogent Biosciences (COGT) to $35 from $34 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results
Cogent Biosciences price target raised to $52 from $39 at Piper Sandler
Piper Sandler raised the firm’s price target on Cogent Biosciences (COGT) to $52 from $39 and keeps an Overweight rating on the shares following Q4 reporting as the company shifts
Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year
“Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway,” said Andrew Robbins, Cogent’s President and ...
Cogent Biosciences sees cash runway into 2028
As of December 31, 2025, Cogent had cash, cash equivalents and marketable securities of $900.8 million. Fourth quarter cash usage was driven largely by non-recurring items, including the repayment of
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastini...
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences announcse U.S. BTD for bezuclastinib
Cogent Biosciences (COGT) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation, BTD, for bezuclastinib in combination with sunitinib for patients with Gast...
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo.
Cogent to initiate New Drug Application submission for bezuclastinib
Cogent Biosciences (COGT) announced that the U.S. Food and Drug Administration, FDA, has agreed to accept its New Drug Application, NDA, for bezuclastinib in combination with sunitinib for patients wi...
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and O...
Cogent Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Bezuclastinib’s three pivotal trials in GIST and systemic mastocytosis showed strong efficacy, with all NDAs set for submission in early 2026 and a U.S. launch planned for later that year. The company is well-funded, expanding its pipeline, and preparing for global commercialization, with ongoing data updates and strategic partnerships under consideration.